Analyst: Open competition for Novo
Rival Biogen Idec is set to hit the market first with its long-acting hemophilia A drug, but Novo Nordisk and Bayer have stronger market positions, which could be hugely important on a conservative market, says a sector analyst.
by Stefan Singh Kailay
The most recent data from Novo Nordisk on its long-acting candidate drug to treat hemophilia A suggests there is a relatively dead heat between the three mayor players on this market: Biogen Idec, Bayer AG and Novo Nordisk.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo expands US partnership
For abonnenter
Novo considers gene therapy
For abonnenter
